New antibiotic shows promise for fast UTI symptom relief in women
NCT ID NCT06597344
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 trial tested the antibiotic gepotidacin in 97 adolescent and adult women with uncomplicated urinary tract infections (UTIs). The goal was to see if symptoms like pain and urgency improved within 24 hours. Researchers measured symptom scores and safety. The study was open-label, meaning everyone knew they were getting the drug, and there was no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gepotidacin
What this could lead to
If successful, this could provide a new oral antibiotic option for quickly easing UTI symptoms in women and teens.
What could go wrong
This is a single-arm, open-label study with no placebo comparison, so results may be less reliable. The trial is also small (97 participants) and completed, so further studies may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY TRACT INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Modesto, California, 95350-5365, United States
-
GSK Investigational Site
Pasadena, California, 91101-2453, United States
-
GSK Investigational Site
San Diego, California, 92120-5259, United States
-
GSK Investigational Site
Valencia, California, 91355, United States
-
GSK Investigational Site
Miami, Florida, 33135, United States
-
GSK Investigational Site
Ormond Beach, Florida, 32174-6302, United States
-
GSK Investigational Site
Palm Springs, Florida, 33406-7671, United States
-
GSK Investigational Site
Palm Springs, Florida, 33461, United States
-
GSK Investigational Site
Plant City, Florida, 33563-4202, United States
-
GSK Investigational Site
Sweetwater, Florida, 33172-2741, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33409-3401, United States
-
GSK Investigational Site
West New York, New Jersey, 07093-2622, United States
-
GSK Investigational Site
New York, New York, 10016-7313, United States
-
GSK Investigational Site
Dayton, Ohio, 45424, United States
-
GSK Investigational Site
Forney, Texas, 75126-4174, United States
-
GSK Investigational Site
Houston, Texas, 77036, United States
-
GSK Investigational Site
Houston, Texas, 77087, United States
-
GSK Investigational Site
Kingwood, Texas, 26537, United States
-
GSK Investigational Site
Mesquite, Texas, 75149, United States
-
GSK Investigational Site
Missouri City, Texas, 77459-4756, United States
-
GSK Investigational Site
Bountiful, Utah, 84010-4943, United States
-
GSK Investigational Site
Morgantown, West Virginia, 26501, United States